ClinicalTrials.Veeva

Menu

Bimatoprost Versus Travoprost at Cairo University

Cairo University (CU) logo

Cairo University (CU)

Status

Completed

Conditions

Glaucoma
Ocular Hypertension

Study type

Observational

Funder types

Other

Identifiers

NCT01092273
Prostaglandins-Cairo-1A

Details and patient eligibility

About

Bimatoprost has been shown to provide effective IOP lowering in patients of all races. Conversely, travoprost has been shown to be more effective in black patients than in Caucasians in some studies. However, Noecker et al 2004 compared bimatoprost with travoprost in African-Americans with glaucoma or OHT, and found that bimatoprost was more likely than travoprost to achieve target pressure at 3 months.

These racial differences in efficacy of these medications warrant further investigations. The investigators study aim to compare the IOP-lowering efficacies of bimatoprost and travoprost in an Egyptian population with primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Sex

All

Ages

20 to 72 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Glaucoma and Ocular Hypertension

Exclusion criteria

  • Any ocular disease or medication that may raise the intraocular pressure.

Trial design

0 participants in 1 patient group

Bimatoprost versus Travoprost

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems